Arsenic Exposure and Hypertension: A Systematic Review by Abhyankar, Lalita N. et al.
494  v o l u m e  120 | n u m b e r 4 | April 2012  •  Environmental Health Perspectives
Review
Hypertension is a major risk factor for mor-
tality and morbidity worldwide (Lopez et al. 
2006; Murray and Lopez 1997; Oparil et al. 
2003; Whitworth 2003). Risk factors for 
hypertension include high salt intake, increased 
body mass index (BMI), genetic predisposition, 
and exposure to psychosocial stress (Oparil 
et al. 2003; Whitworth 2003). Additional evi-
dence, however, suggests that environmental 
factors play a role in hypertension development 
(Houston 2007; Klahr 2001; Laclaustra et al. 
2009; Navas-Acien et al. 2007, 2008; Oparil 
et al. 2003; Tellez-Plaza et al. 2008; Vaziri 
2008). The identification and mitigation of 
environmental exposures related to hyperten-
sion could contribute to reducing the world-
wide burden of hypertension-related disease.
Among environmental exposures, epidemi-
ologic and experimental evidence supports the 
possibility that arsenic plays a role in hyperten-
sion and other cardiometabolic diseases [Chen Y 
et al. 2011; Medrano et al. 2010; Navas-Acien 
et al. 2005; Smedley and Kinniburgh 2002; 
U.S. Department of Health and Human 
Services (DHHS) 2005; Wang CH et al. 2007; 
Wu et al. 1989]. Arsenic-contaminated drink-
ing water represents a major public health 
problem internationally (Chappell et al. 2002; 
Chen CJ et al. 1995; Chilvers and Peterson 
1987; Hinkle and Polette 1999; Mukherjee 
et al. 2006; Rahman et al. 1999). The World 
Health Organization and U.S. Environmental 
Protection Agency (EPA) standard for arsenic 
levels in drinking water is 10 μg/L (DHHS 
2005; Whitworth 2003). In the United States 
alone, millions of persons are exposed to arse-
nic concentrations > 10 μg/L; whereas per-
sons in Bangladesh, China, India, Cambodia, 
Ghana, Argentina, Mexico, and other countries 
around the world are exposed to arsenic levels 
in drinking water that are well beyond 10 μg/L 
(Navas-Acien et al. 2005; DHHS 2005). 
Epidemiologic studies conducted in arsenic-
endemic areas in Taiwan and Bangladesh have 
found a positive relationship between inor-
ganic arsenic exposure from drinking water and 
hypertension (Chen CJ et al. 1995; Rahman 
et al. 1999). Experimental studies have indi-
cated that arsenic exposure may be involved in 
the development of hypertension through the 
promotion of inflammation, oxidative stress, 
and endothelial dysfunction (Aposhian et al. 
2003; Balakumar et al. 2008; Lee et al. 2003; 
Smedley and Kinniburgh 2002; DHHS 2005).
To evaluate the potential   relationship 
between arsenic and hypertension, we 
conducted a systematic review of epidemio-
logic studies that have investigated the asso-
ciation between inorganic arsenic exposure 
(using environmental measures or biomark-
ers) and hypertension outcomes [using hyper-
tension status and systolic and diastolic blood 
pressure (SBP and DBP, respectively)].
Methods
Search strategy and data abstraction. We 
searched PubMed (http://www.ncbi.nlm.nih.
gov/pubmed/, Embase (http://www.embase.
com/home), and TOXLINE (http://toxnet.
nlm.nih.gov/cgi-bin/sis/htmlgen?TOXLINE) 
databases to find all published observational 
studies evaluating the relationship between 
arsenic exposure with hypertension or BP lev-
els using the free text and Medical Subject 
Headings (MeSH) terms “arsenic,” “arseni-
cals,” “arsenate,” or “arsenite” and “hyperten-
sion” or “blood pressure.” The search period 
was January 1966 through March 2011 with 
no language restrictions (Figure 1).
Two investigators (L.N.A. and M.R.J.) 
reviewed each paper and applied the study 
selection criteria (Figure 1). Epidemiologic 
studies with data on arsenic exposure and 
hypertension outcomes were included. We 
excluded non  original reports, experimental 
studies, case reports and case series, and stud-
ies without measures of arsenic exposure or 
hypertension end points. We also excluded 
one study that used hypertension mortality as 
the only end point (Lewis et al. 1999) and two 
reports (Hsueh et al. 2005; Huang et al. 2007) 
that used the same study population as another 
included study (Chen CJ et al. 1995). The 
two investigators, L.N.A. and M.R.J., inde-
pendently abstracted the study data, includ-
ing design, study population (location, age, 
and sex distribution), sample size, arsenic 
assessment and exposure levels, hypertension 
outcomes, study results (measures of associa-
tion), and potential confounders accounted 
for in the statistical analysis. Authors were 
contacted for information unavailable in the 
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Ba c k g r o u n d: Environmental exposure to arsenic has been linked to hypertension in persons living 
in arsenic-endemic areas.
oB j e c t i v e: We summarized published epidemiologic studies concerning arsenic exposure and hyper-
tension or blood pressure (BP) measurements to evaluate the potential relationship.
da t a s o u r c e s a n d e x t r a c t i o n: We searched PubMed, Embase, and TOXLINE and applied pre-
determined exclusion criteria. We identified 11 cross-sectional studies from which we abstracted 
or derived measures of association and calculated pooled odds ratios (ORs) using inverse-variance 
weighted random-effects models.
da t a synthesis: The pooled OR for hypertension comparing the highest and lowest arsenic 
exposure categories was 1.27 [95% confidence interval (CI): 1.09, 1.47; p-value for heterogene-
ity = 0.001; I2 = 70.2%]. In populations with moderate to high arsenic concentrations in drinking 
water, the pooled OR was 1.15 (95% CI: 0.96, 1.37; p-value for heterogeneity = 0.002; I2 = 76.6%) 
and 2.57 (95% CI: 1.56, 4.24; p-value for heterogeneity = 0.13; I2 = 46.6%) before and after 
excluding an influential study, respectively. The corresponding pooled OR in populations with 
low arsenic concentrations in drinking water was 1.56 (95% CI: 1.21, 2.01; p-value for hetero-
geneity = 0.27; I2 = 24.6%). A dose–response assessment including six studies with available data 
showed an increasing trend in the odds of hypertension with increasing arsenic exposure. Few stud-
ies have evaluated changes in systolic and diastolic BP (SBP and DBP, respectively) measurements 
by arsenic exposure levels, and those studies reported inconclusive findings.
co n c l u s i o n: In this systematic review we identified an association between arsenic and the 
prevalence of hypertension. Interpreting a causal effect of environmental arsenic on hypertension is 
limited by the small number of studies, the presence of influential studies, and the absence of pro-
spective evidence. Additional evidence is needed to evaluate the dose–response relationship between 
environmental arsenic exposure and hypertension.
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published reports. For studies with multiple 
levels of adjustment, we abstracted the meas-
ure of association obtained from the model 
adjusted for the most covariates after confirma-
tion that adjustment did not markedly modify 
the conclusions of any individual study. For 
studies that were not in English (138 of 865), 
the full text of the article was translated by a 
native speaker if the information in the abstract 
was insufficient to include/exclude the article. 
Discrepancies were resolved by consensus. The 
quality of the included studies was evaluated by 
adapting the criteria developed by Longnecker 
et al. (1988) and Appel et al. (2002).
Statistical analysis. For studies that reported 
hypertension, we abstracted (Chen CJ et al. 
1995; Chen Y 2007; Jones et al. 2011; Rahman 
et al. 1999; Zierold et al. 2004) or derived 
(Guo et al. 2007; Wang SL et al. 2007; Yildiz 
et al. 2008) odds ratios (ORs) and prevalence 
ratios for hypertension and their standard errors 
from the published data. For three studies with 
hypertension data but no available measures 
of association, we estimated the OR and 95% 
confidence interval (CI) for hypertension by 
arsenic categories using the number of cases and 
non  cases in the exposed and unexposed groups 
(Guo et al. 2007; Wang SL et al. 2007; Yildiz 
et al. 2008). For summary purposes, we pooled 
OR estimates comparing hypertension in the 
highest and lowest categories of arsenic expo-
sure from individual studies using an inverse-
variance weighted random-effects model. 
Pooled ORs were calculated for all studies and 
separately for studies conducted in popu  lations 
exposed to moderate-to-high arsenic levels and 
for studies conducted in populations exposed 
to low arsenic levels. Heterogeneity was quanti-
fied with the I2 statistic, an index that describes 
the proportion of the total variation in pooled 
estimates due to heterogeneity (Higgins and 
Thompson 2002). The relative influence of 
each study on pooled estimates was estimated 
by omitting one study at a time. Finally, we 
assessed publication bias using funnel plots. For 
studies that reported hypertension results for 
three or more arsenic categories, we evaluated 
the dose–response relationship over the range 
of arsenic levels (Chen CJ et al. 1995; Jones 
et al. 2011; Rahman et al. 1999; Wang SL et al. 
2007; Zierold et al. 2004). All statistical analy-
ses were performed using Stata software, version 
11.0 (StataCorp, College Station, TX, USA).
For studies that reported SBP (Chen Y et al. 
2007; Dastgiri et al. 2010; Jensen and Hansen 
1998; Jones et al. 2011; Kwok et al. 2007) and 
DBP (Chen Y et al. 2007; Dastgiri et al. 2010; 
Jones et al. 2011; Kwok et al. 2007) levels, we 
abstracted (Jones et al. 2011; Kwok et al. 2007) 
or derived (Chen Y et al. 2007; Dastgiri et al. 
2010; Jensen and Hansen 1998) the differ-
ence in BP levels comparing the highest and 
lowest categories of arsenic exposure. Because 
the number of studies was small and because 
the largest study (Chen Y et al. 2007) did not 
provide enough information to calculate CIs, 
these results are presented descriptively, and no 
pooled estimate was calculated.
Results
Study characteristics. Eleven studies, pub-
lished between 1995 and 2011, were identified 
(Table 1). All studies meeting the inclusion 
criteria were cross-sectional and published in 
English. Combined, the studies covered arse-
nic exposure and hypertension outcomes for 
> 20,000 individuals. Eight studies were con-
ducted at moderate to high levels of exposure 
(average levels in drinking water ≥ 50 μg/L or 
occupational studies) (Chen CJ et al. 1995; 
Chen Y 2007; Dastgiri et al. 2010; Guo et al. 
2007; Jensen and Hansen 1998; Kwok et al. 
2007; Rahman et al. 1999; Yildiz et al. 2008), 
and three studies were conducted at low levels 
of exposure (average levels in drinking water 
< 50 μg/L) (Jones et al. 2011; Wang SL et al. 
2007; Zierold et al. 2004). Ten studies were 
conducted in general populations (two from 
Taiwan, two from Bangladesh, two from Inner 
Mongolia, two from the United States, one 
from Turkey, and one from Iran) (Chen CJ 
et al. 1995; Chen Y 2007; Dastgiri et al. 2010; 
Guo et al. 2007; Jones et al. 2011; Kwok et al. 
2007; Rahman et al. 1999; Wang SL et al. 
2007; Yildiz et al. 2008; Zierold et al. 2004). 
One study was conducted in an occupational 
setting in Denmark (Jensen and Hansen 1998). 
Five studies measured arsenic concentrations in 
drinking water (Chen CJ et al. 1995; Chen Y 
2007; Kwok et al. 2007; Rahman et al. 1999; 
Zierold et al. 2004), three compared areas of 
high and low arsenic concentrations in drink-
ing water (Dastgiri et al. 2010; Guo et al. 2007; 
Yildiz et al. 2008), two studies used biomarkers 
(hair, Wang SL et al. 2007; urine, Jones et al. 
2011), and one study assigned arsenic exposure 
based on job title (Jensen and Hansen 1998). 
Eight studies assessed hypertension as the end 
point of interest (Chen CJ et al. 1995; Chen Y 
2007; Guo et al. 2007; Jones et al. 2011; 
Rahman et al. 1999; Wang SL et al. 2007; 
Yildiz et al. 2008; Zierold et al. 2004), five stud-
ies reported differences in mean SBP (Chen Y 
et al. 2007; Dastgiri et al. 2010; Jensen and 
Hansen 1998; Jones et al. 2011; Kwok et al. 
2007), and four studies reported differences in 
mean DBP (Chen Y et al. 2007; Dastgiri et al. 
2010; Jones et al. 2011; Kwok et al. 2007).
Quality assessment. Five studies measured 
arsenic in drinking water at the individual 
level (Chen Y et al. 2007; Jones et al. 2011; 
Kwok et al. 2007; Wang SL et al. 2007; Yildiz 
Figure 1. Summary of search and screening process.
aA total of 138 studies were not in English. bChen Y et al. (2007) and Jones et al. (2011) were the only studies including both 
hypertension and BP level end points.
Eligible studies for ﬁnal review: 14
Distinct references identiﬁed: 865a
  • PubMed search: 393
  • Embase (excluding PubMed): 385
  • TOXLINE (excluding PubMed): 87
Excluded (based on initial exclusion criteria): 851
  • Review, editorial, comment, no original data
  • Animal study or no data in humans
  • Case report or no control group
  • No data on arsenic levels
  • No hypertension or blood pressure outcomes
Excluded (based on secondary exclusion criteria): 3
  • Hypertensive mortality used as an end point (n = 1)
  • Same study population (n = 2)
Studies included in ﬁnal review: 11
  • Cross-sectional studies: 11
   – Hypertension: 8
   – Blood pressure: 5b
  • Arsenic levels
   – Moderate to high: 8
   – Low: 3
  • Biomarker measurements: 2
  • Occupational studies: 1Abhyankar et al.
496  v o l u m e  120 | n u m b e r 4 | April 2012  •  Environmental Health Perspectives
et al. 2008); three of these studies measured 
individual arsenic exposure based on meas-
ured well water concentrations (Chen Y et al. 
2007; Kwok et al. 2007; Yildiz et al. 2008), 
and two studies used a biomarker of expo-
sure (Table 2) (Jones et al. 2011; Wang SL 
et al. 2007). Five studies defined hypertension 
based on established cutoffs for SBP and DBP 
levels measured with a standardized protocol 
and self-reported physician diagnosis or anti-
hypertensive treatment (Chen CJ et al. 1995; 
Chen Y 2007; Jones et al. 2011; Rahman et al. 
1999; Wang SL et al. 2007). Five of the 11 
studies did not adjust for potential confounders 
(Dastgiri et al. 2010; Guo et al. 2007; Jensen 
and Hansen 1998; Wang SL et al. 2007; Yildiz 
et al. 2008). Other studies adjusted at least for 
age, sex, and BMI.
ORs estimates for hypertension. For the 
association of hypertension with arsenic expo-
sure, five of the eight studies found a positive 
association (Chen CJ et al. 1995; Guo et al. 
2007; Rahman et al. 1999; Wang SL et al. 
2007; Zierold et al. 2004). Among the stud-
ies that assessed hypertension at moderate 
to high levels of exposure, the OR estimates 
comparing highest with lowest arsenic expo-
sure groups ranged from 0.71 (95% CI: 0.18, 
2.63) in a small study in Turkey (Yildiz et al. 
2008) to 16.5 (95% CI: 2.8, 668.5) in a study 
in Inner Mongolia (Figure 2) (Guo et al. 
2007). The two studies from Bangladesh pro-
vided inconsistent results: an OR of 3.0 (95% 
Table 1. Epidemiological studies of arsenic exposure and blood pressure end points.
Reference n
Percent 
men
Arsenic Definition of 
hypertension
No. of 
cases
Adjustment 
variables Country Population Age  Marker Mean ± SD Range SBP/DBP determinations
Moderate to high arsenic levels in drinking water (average ≥ 50 μg/L) or occupationally exposed populations
Chen CJ et al. 
1995
Southwest 
Taiwan
General 898 42.5 ≥ 30 years CAE in 
groundwater
NR 0 to > 18.5 
mg/L-years
Mean of three SBP and DBP 
measures after 20 min of 
rest with mercury 
sphygmomanometer
SBP ≥ 160 
mmHg, 
DBP ≥ 95 
mmHg, HT 
medication
168 Age, sex, BMI, 
diabetes, 
proteinuria, 
fasting serum 
triglycerides
Jensen and 
Hansen 
1998 
Denmark Occupational 59 NR Mean age, 
37 years
Occupational 
exposure 
(confirmed in 
urine)
Exposed,a 
14.8 μg /g 
creatinine
Unexposed, 
7.9 μg /g
Exposed,a 
7.6–195.6
Unexposed, 
3.9–29.1
Mean of three SBP and DBP 
measures after 10 min of 
rest with digital equipment
NA NA None
Rahman et al. 
1999
Central and 
eastern 
Bangladesh
General 1,595 59.7 30–85 years CAE in 
groundwater
NR 0 to > 10 
mg/L-years 
Lowest BP of three measures 
used; two additional 
measurements taken for 
individuals w/HT
SBP ≥ 140 
mmHg 
and/or 
DBP ≥ 90 
mmHg
207 Age, sex, BMI
Chen Y et al. 
2007
Araihazar, 
Bangladesh
General 11,458 42.8 ≥ 18 years TWA 
concentration 
in groundwater
NR 0.1–864.0 μg/L SBP and DBP measured 
by trained clinicians 
with automatic 
sphygmomanometer after 
2–3 min of rest
Two or more measures taken 
for persons with SBP/DBP 
≥ 140/90 mmHg at first 
measure
Lowest BP used
SBP ≥ 140 
mmHg 
and/or 
DBP ≥ 90 
mmHg
1,360 Age, sex, BMI, 
smoking, 
education, 
daily water 
consumption
Guo et al. 
2007
Inner 
Mongolia, 
China
General 869 NA Childbearing 
age
High vs. low 
arsenic in 
water
NR 50–1,860 μg/L NA NR 56 None
Kwok et al. 
2007
Inner 
Mongolia, 
China
General 
(postpartum)
3,260 0.0 17–45 years Individual 
groundwater 
concentration
NR < LODa to 
> 100 μg/L
SBP and DBP measured after 
5 min of rest at 6 weeks 
post  partum using 
appropriately sized cuff
NA NA Age, body 
weight
Yildiz et al. 
2008
Dulkadir and 
Alikoy, 
Turkey
General 80 100 Mean age, 
35 years
High vs. low 
arsenic in 
water
659 ± 323 μg/L 422–1,066 μg/L NR NR 14 None
Dastgiri et al. 
2010
Ghopuz and 
Mayan, 
Iran
General 208 42.7 ≥ 6 years; 
mean age, 
33 years
High vs. low 
arsenic in 
water
1.031 mg/L NR SBP and DBP measured once 
after 10 min rest using 
portable sphygmomanometer
NA NA None
Low arsenic levels in drinking water (average < 50 μg/L)
Zierold et al. 
2004
Wisconsin, 
USA
General 1,185 NA ≥ 35 years Individual 
groundwater 
concentration
Median, 
2 μg/L
0–2,389 μg/L NA Self-
reported
NR Age, sex, BMI, 
smoking
Wang SL 
et al. 2007 
Central 
Taiwan
General 432 44.2 35–64 years Hair, total 
arsenic
0.071 μg/g 
creatinine
NR Mean of two SBP and DBP 
measures using mercury 
sphygmomanometer with 
appropriately sized cuff
Two measures carried out 
30 min apart; if difference 
> 5%, BP measured third 
time and two closest used
SBP ≥ 140 
mmHg 
and/or 
DBP ≥ 90 
mmHg, HT 
medication
NR None
Jones et al. 
2011
USA General 4,167 49.0 Mean age, 
47.7 years
Urine arsenic 
(μg/L)
Median, 
8.3 μg/L
< 0.6 to 
> 17.1 μg/L
Mean of three or four SBP 
and DBP measures by 
certified examiners using 
appropriately sized cuff after 
5 min rest
SBP ≥ 140 
mmHg 
and/or 
DBP ≥ 90 
mmHg, HT 
medication
1,761 Age, sex, race, 
ethnicity, urine 
creatinine, 
education, 
BMI, serum 
cotinine, 
arsenobetaine
Abbreviations: BP, blood pressure; CAE, cumulative arsenic exposure, assessed by measuring the arsenic concentration in groundwater at the village level multiplied by the drinking duration at the 
individual level (Chen CJ et al. 1995); HT, hypertension; LOD, limit of detection; NA, not available; NR, not reported; TWA, time-weighted arsenic concentration, calculated as ΣCiTi/ΣTi, where “Ci and 
Ti denote the well arsenic concentration and drinking duration for the ith well” (Chen Y et al. 2007). 
aNot used in the statistical analysis; reported exclusively to confirm arsenic differences in exposed and unexposed participants.Arsenic and hypertension
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CI: 1.5, 5.8) in the study by Rahman et al. 
(1999) and an OR of 1.02 (95% CI: 0.84, 
1.23) in the study by Chen Y et al. (2007). 
Among the studies that assessed hyperten-
sion at low levels of exposure, the OR esti-
mates comparing highest with lowest arsenic 
exposure groups ranged from 1.17 (95% CI: 
0.75, 1.83) in a study in the general U.S. 
population (Jones et al. 2011) to 2.00 (95% 
CI: 1.21, 3.31) in a study in central Taiwan 
(Wang SL et al. 2007).
The pooled OR of hypertension compar-
ing the highest and lowest arsenic exposure 
categories in the eight studies with avail-
able information on hypertension was 1.27 
(95% CI: 1.09, 1.47; p-value for heterogene-
ity = 0.001; I2 = 70.2%). The corresponding 
pooled OR in the five studies with moderate 
to high arsenic exposure was 1.15 (95% CI: 
0.96, 1.37; p-value for heterogeneity = 0.002; 
I2 = 76.6%), with the study by Chen Y et al. 
(2007) being highly influential. Excluding 
that study, the pooled OR was 2.57 (95% CI: 
1.56, 4.24; p-value for heterogeneity = 0.13; 
I2 = 46.6%). The pooled OR comparing the 
highest and lowest arsenic exposure categories 
in the three studies with low arsenic exposure 
was 1.56 (95% CI: 1.21, 2.01; p-value for 
heterogeneity = 0.27; I2 = 24.6%). We also 
restricted the overall pooled analysis to stud-
ies with multi  variable adjusted ORs (pooled 
OR = 1.22; 95% CI: 1.04, 1.42) (Chen CJ 
et al. 1995; Chen Y 2007; Jones et al. 2011; 
Rahman et al. 1999; Zierold et al. 2004), 
studies with a standard hypertension defi-
nition (pooled OR = 1.21; 95% CI: 1.03, 
1.42) (Chen CJ et al. 1995; Chen Y 2007; 
Jones et al. 2011; Rahman et al. 1999; 
Wang SL et al. 2007), and studies with indi-
vidual assessment of arsenic exposure (pooled 
OR = 1.19; 95% CI: 1.02, 1.38) (Chen Y 
et al. 2007; Jones et al. 2011; Wang SL et al. 
2007; Zierold et al. 2004). Funnel plots did 
not suggest the presence of publication or 
related biases (data not shown).
We evaluated the dose response for six 
studies with ORs reported for three or more 
categories (Figure 3) (Chen CJ et al. 1995; 
Chen Y 2007; Jones et al. 2011; Rahman et al. 
1999; Wang SL et al. 2007; Zierold et al. 
2004). Among them, the Chen Y et al. (2007) 
study in Bangladesh showed no dose–response 
relationship. Compared with the baseline 
category, the other study from Bangladesh 
(Rahman et al. 1999) and the study from 
Taiwan (Chen CJ et al. 1995) showed 
increased prevalence of hypertension for most 
of the arsenic exposure categories. Studies con-
ducted at low levels of exposure in drinking 
water (Jones et al. 2011; Wang SL et al. 2007; 
Zierold et al. 2004) showed an increased 
prevalence of hypertension throughout the 
range of arsenic exposure levels, although the 
Table 2. Criteria for evaluation of design and data analysis of epidemiological studies on arsenic and hypertension.a
Moderate to high arsenic levels  
(average ≥ 50 μg/L)b
Low arsenic levels  
(average < 50 μg/L)c
Criteria
Chen CJ 
et al. 
1995
Jensen and 
Hansen 
1998 
Rahman 
et al. 
1999
Chen Y 
et al. 
2007
Guo 
et al. 
2007
Kwok 
et al. 
2007
Yildiz 
et al. 
2008
Dastgiri 
et al. 
2010
Zierold 
et al. 
2004
Wang SL 
et al. 
2007
Jones 
et al. 
2011
BP was measured on participant in a seated position, using 
multiple SDP and DBP measures on the same arm with an 
appropriately sized cuff and after several minutes of restd
Yes Yes Yes Yes No Yes No No No Yes Yes
Standardized hypertension definition Yes — Yes Yes No — No — No Yes Yes
Arsenic exposure assessed using a biomarker No No No No No No No No No Yes Yes
Arsenic exposure assessed at the individual level No No No Yes No Yes No No Yes Yes Yes
Response rate at least 70% Yes No Yes Yes No No No Yes No No Yes
Interviewer was blinded with respect to the participant 
case or exposure status
Yes No No Yes No Yes No No Yes Yes Yes
Same exclusion criteria applied to all participants Yes No Yes Yes Yes Yes Yes Yes Yes Yes Yes
Data collected in a similar manner for all participants Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Noncases would have been cases had they developed 
hypertension
Yes — Yes Yes No — No — No Yes Yes
Authors controlled for relevant confounding factors in 
addition to age, sex, and BMI
Yes No Yes Yes No Yes No No Yes No Yes
—, Not applicable.
aCriteria modified from Longnecker et al. (1988) and Appel et al. (2002). bArsenic exposure via drinking water or occupation. cArsenic exposure via drinking water only. dStudies indicat-
ing that they used the WHO protocol were considered to meet the criteria for blood pressure measurement. 
Figure 2. ORs of hypertension by arsenic exposure levels. The area of each square is proportional to the inverse of the variance of the estimated log OR. 
Horizontal lines represent 95% CIs. In the Chen Y et al. (2007) study, arsenic concentrations in drinking water were estimated based on time-weighted arsenic 
concentrations (ΣCiTi /ΣTi, where “Ci and Ti denote the well arsenic concentration and drinking duration for the ith well”).
Study  Cases/controls  Marker  Exposure group  Reference group  OR (95% CI)
Moderate to high arsenic levels in drinking water
Chen CJ et al. 1995  75/280  Water  > 18.5 mg/L-years  0 mg/L-years  2.90 (1.10, 7.30)
Rahman et al. 1999  71/314  Water  > 10 mg/L-years  0 mg/L-years  3.00 (1.50, 5.80)
Guo et al. 2007  56/813  Water  > 50 µg/L  < 50 µg/L  16.54 (1.07, 2.55)
Chen Y et al. 2007   554/3,872  Water  176.1–864.0 µg/L  0.1–8.0 µg/L  1.02 (0.84, 1.23)
Yildiz et al. 2008  14/66  Water  > 422 µg/L  < 50 µg/L  0.71 (0.18, 2.63)
Low arsenic levels in drinking water
Zierold et al. 2004  NA  Water  > 10 µg/L  < 2 µg/L  1.68 (1.13, 2.49)
Wang SL et al. 2007  120/168  Hair  Tertile 3  Tertile 1  2.00 (1.21, 3.31)
Jones et al. 2011  446/622  Urine  > 17.1 µg/L  < 4.2 µg/L  1.17 (0.75, 1.83) 
0.5 12 51 0
Hypertension OR
20Abhyankar et al.
498  v o l u m e  120 | n u m b e r 4 | April 2012  •  Environmental Health Perspectives
association was not statistically significant for 
the intermediate arsenic categories.
Difference in BP level estimates. For the 
association of arsenic exposure with BP levels, 
three of five studies found a positive asso-
ciation with SBP (Dastgiri et al. 2010; Jensen 
and Hansen 1998; Kwok et al. 2007), and 
two of four studies found a positive associ-
ation with DBP (Figure 4) (Dastgiri et al. 
2010; Kwok et al. 2007). The difference in 
BP levels comparing the highest and lowest 
arsenic exposure categories ranged from –0.79 
to 30.0 mmHg for SBP and from –0.65 to 
11.04 mmHg for DBP. Only two studies 
adjusted for hypertension risk factors (Jones 
et al. 2011; Kwok et al. 2007).
Discussion
This systematic review identified an association 
between arsenic exposure and the prevalence of 
hypertension. The association was present both 
in studies conducted in areas with moderate-
to-high arsenic exposure levels and in studies 
conducted in areas with low exposure levels. 
A clear dose–response was observed in several 
studies, and experimental evidence supports the 
hypertensive effects of arsenic. The interpreta-
tion of this association regarding the causal 
effect of arsenic on hypertension, however, is 
limited by the small number of studies, the 
heterogeneity across studies, and the absence of 
prospective evidence. In addition, some stud-
ies were affected by additional methodological 
limitations such as the lack of standard hyper-
tension definitions, individual assessment of 
arsenic exposure, or appropriate adjustment for 
relevant confounders. The evidence is particu-
larly scarce for low levels of exposure and for 
evaluating the association with SBP and DBP 
levels as continuous outcomes. Overall, the 
evidence is suggestive but insufficient to infer 
a causal relationship between environmental 
arsenic exposure and hypertension.
Two studies from areas with high arse-
nic levels in drinking water in southwestern 
Taiwan (Chen CJ et al. 1995) and Bangladesh 
(Rahman et al. 1999) and two studies con-
ducted in areas with low levels of arsenic in 
drinking water in Wisconsin (Zierold et al. 
2004) and central Taiwan (Wang SL et al. 
2007) showed consistent associations of arsenic 
exposure with the prevalence of hypertension. 
These four studies also showed a consistent 
dose–response increase in the prevalence of 
hypertension with increasing arsenic exposure.
Discrepancies in the association between 
arsenic and the prevalence of hypertension were 
observed in four studies (Chen Y et al. 2007; 
Dastgiri et al. 2010; Guo et al. 2007; Yildiz 
et al. 2008). The study with the strongest asso-
ciation (OR = 16.54; Guo et al. 2007) and the 
study with the inverse association (OR = 0.71; 
Yildiz et al. 2008) had small numbers of cases, 
provided no definition of hypertension, and 
incorporated no adjustment for relevant con-
founders. Both studies were highly imprecise 
with large CIs. The two null studies were large 
high-quality studies conducted in Bangladesh 
and the United States (Chen Y et al. 2007; 
Jones et al. 2011). The study in Bangladesh 
found no dose–response relationship, despite 
assessing arsenic at the individual level and 
Figure 3. Evaluation of dose response for arsenic exposure and hypertension. Blue symbols indicate stud-
ies conducted in populations with low arsenic levels in drinking water (average < 50 μg/L); black symbols 
indicate studies conducted in populations with moderate-to-high arsenic levels in drinking water (average 
> 50 μg/L). The size of each data point is inversely weighted based on the inverse of the variance of the 
estimated log OR. For the Wang SL et al. (2007) study, actual arsenic levels for each hair tertile were not 
provided, and values defining the arsenic exposure tertiles were approximated based on the geometric 
mean of hair arsenic.
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Figure 4. Difference (95% CI) in mean SBP and DBP by arsenic exposure level. The area of each square is proportional to the inverse of the variance of the esti-
mated. NA: not available [the study by Chen Y et al. (2007) did not include standard errors or data that would allow estimation of the standard errors for mean 
systolic and diastolic blood pressure SBP and DBP levels, and a 95% CI could not be calculated for this study]. 
aProfessions include taxidermists, garden fence makers, weekend cottage constructors, wood impregnators, electric pylon impregnators, and new house constructors (Jensen and 
Hansen 1998).
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Jensen et al. 1998  Worka  Exposed  Unexposed  34/25  7.60 (2.86, 12.34)  NA
Kwok et al. 2007  Water  > 100 µg/L  < 20 µg/L  563/5,982  6.83 (5.39, 8.27)  3.08 (1.84, 4.31)
Chen Y et al. 2007  Water  > 1.76.1 µg/L  < 8.0 µg/L  2,214/2,293  0.1 (NA, NA)  1.2 (NA, NA)
Dastigiri et al. 2010  Water  High arsenic  Low arsenic  101/107  30.0 (24.73, 35.27)  11.04 (7.79, 14.21)
Jones et al. 2011  Urine  > 17 µg/L  < 4.2 µg/L  446/622  –0.79 (–4.06, 2.47)  –0.65 (–2.86, 1.56)Arsenic and hypertension
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defining hypertension based on BP measures 
(Chen Y et al. 2007). However, this study did 
find an association between arsenic levels in 
drinking water with systolic hypertension and 
pulse pressure levels among participants with 
low folate and vitamin B intake levels (Chen Y 
et al. 2007), whereas subgroup analyses by 
folate and vitamin B concentrations were con-
ducted in the study in the general U.S. popula-
tion, with no differences (Jones et al. 2011). In 
the study conducted among the general U.S. 
population, the association between arsenic 
exposure and hypertension was not statistically 
significant, and it was consistent with no asso-
ciation (Jones et al. 2011). However, the mag-
nitude of the association was compatible with 
a small increased prevalence of hypertension 
and consistent with the dose–response trend 
observed in other studies conducted at low-
to-moderate exposure levels in Wisconsin and 
central Taiwan (Jones et al. 2011; Wang SL 
et al. 2007; Zierold et al. 2004).
The potential association between expo-
sure to inorganic arsenic and the development 
of hypertension is supported by experimental 
and mechanistic evidence, especially at high 
exposure levels. Arsenic promotes inflamma-
tion activity, oxidative stress, and endothe-
lial dysfunction through several mechanisms 
including the activation of stress response 
transcription factors such as activator pro-
tein-1 and nuclear factor-κB (Bunderson et al. 
2002; Carmignani et al. 1985; Chen Y et al. 
2007; Druwe and Vaillancourt 2010; Pi et al. 
2000). In vitro, arsenite altered vascular tone 
in blood vessels by suppressing vasorelaxation 
(Lee et al. 2003) and increased the expres-
sion of cyclooxygenase-2 in endothelial cells 
(Bunderson et al. 2002; Tsai et al. 2002). In 
animal models, arsenite increased superox-
ide accumulation and impaired nitric oxide 
formation in endothelial cells (Barchowsky 
et al. 1996, 1999; Lee et al. 2005). Finally, the 
hypertensive effects of arsenic could be related 
to the possible chronic kidney effects of arse-
nic (Chen JW et al. 2011; Hsueh et al. 2009). 
Additional experimental studies using arsenic 
exposure levels relevant to human populations 
are needed to characterize the etiopathogenesis 
of potential hypertensive effects of arsenic.
Conclusions
This is the first systematic review and meta-
analysis evaluating the relationship between 
arsenic exposure and hypertension end points. 
We identified a positive association between 
elevated arsenic exposure and the prevalence of 
hypertension, but the implications of this asso-
ciation from a causal perspective are unclear 
because of the limited number of studies as 
well as the studies’ cross-sectional design, and 
methodological limitations. Prospective cohort 
studies in populations exposed to a wide range 
of arsenic exposure levels, from low through 
moderate-to-high levels of exposure, are needed 
to better characterize the relationship between 
arsenic and hypertension. Because of the wide-
spread exposure to arsenic worldwide and the 
high burden of disease caused by hyperten-
sion, it is important that high-quality prospec-
tive studies are conducted with individual level 
assessment of arsenic exposure and standardized 
measurements of BP. The studies should evalu-
ate the shape of the dose response and whether 
the magnitude of the association is different in 
susceptible populations, including populations 
with nutritional deficiencies. If the hyperten-
sive effects of arsenic are confirmed, they could 
partly explain the association between arsenic 
and cardiovascular disease (Chen Y et al. 2011; 
Medrano et al. 2010; Navas-Acien et al. 2005; 
Smedley and Kinniburgh 2002; DHHS 2005; 
Wang CH et al. 2007; Wu et al. 1989). Given 
the widespread arsenic exposure through drink-
ing water and food, even a modest effect of 
arsenic on hypertension could have a substan-
tial impact on morbidity and mortality (Kwok 
2007; Manson et al. 1992).
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